MedPath

Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries

Phase 1
Completed
Conditions
Peripheral Arterial Disease
Interventions
Device: paclitaxel coated balloon catheter (device with drug)
Registration Number
NCT00472472
Lead Sponsor
University Hospital, Saarland
Brief Summary

The PACCOCATH FEM study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in prevention of restenosis after femoropopliteal angioplasty.

Detailed Description

Background: Treatment of patients with peripheral arterial disease (PAD) in the femoropopliteal arteries by percutaneous intervention is still limited by high rates of restenosis. The aim of the present study is to evaluate the efficacy and safety of a novel method of short time local drug delivery based on a paclitaxel-coated balloon in femoropopliteal arteries.

Methods and results: The double-blind and randomized study enrolled n=79 patients with occlusion or stenosis of femoropopliteal arteries. Inclusion criteria were clinical Rutherford stage 1-5, occlusion or hemodynamic relevant stenosis (≥ 70 % diameter) of femoropopliteal arteries and successful guiding wire recanalization. The primary endpoint was the late lumen loss after 6 months follow-up as seen in angiography. Secondary endpoints included the rate of restenosis (a binary variable), change of ankle brachial index (ABI), rutherford class and major adverse events.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
87
Inclusion Criteria
  • Rutherford stage 1, 2, 3, 4 oder 5
  • Occlusion or Stenosis of Superficial femoral and/or popliteal artery
  • Successful guide wire passage of the lesion
  • Patient suitable of vascular surgery in case of complication
  • Written consent
  • Patient is willing to take part in follow up examinations within the study
Exclusion Criteria
  • Acute ischemia
  • Distal run off less than one vessel
  • Pregnancy
  • Hyperthyroidism
  • Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3
  • Life expectancy less than two years
  • Patients not willing to enter the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1paclitaxel coated balloon catheter (device with drug)PTA
2paclitaxel coated balloon catheter (device with drug)PTA with Paccocath
Primary Outcome Measures
NameTimeMethod
angiographic late lumen loss6 months
Secondary Outcome Measures
NameTimeMethod
binary restenosis rate; major adverse events18 months

Trial Locations

Locations (2)

Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum

🇩🇪

Berlin, Germany

Institut für Diagnostische Radiologie und Neuroradiologie, Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität

🇩🇪

Greifswald, Germany

© Copyright 2025. All Rights Reserved by MedPath